Diagnostics & biomarkers

Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.

When Brain Surgery Is Too Risky, Patients Still Need a Molecular Answer

MASH, a serious fatty liver disease, is becoming a cardiometabolic condition

Gastric Cancer Gets a New Biomarker Access Signal

Brain-Bleed Care Still Has a Last-Mile Problem

Cholesterol prevention is moving earlier. Is Europe ready to treat inherited risk before adulthood?

Gastric Cancer Gets a New Biomarker Access Signal

Dementia Is Not the End of Personhood

MRD Testing Moves From Prognosis Toward Treatment Action
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
